In its continued bid to waylay the launch of MSN Pharmaceuticals’ proposed Entresto generic, Novartis has told a federal ...

Researchers have zeroed in on yet another possible ocular concern for diabetes patients who take popular GLP-1 therapies in a ...

Days after FDA Commissioner Marty Makary said that the agency planned to review the safety of abortion pill mifepristone, ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Argenx has signed on as an early partner to a newly launched initiative from media companies NBCUniversal Local and Digital ...

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in ...

The Council is now set to begin negotiations with the European Parliament on the package, after which the rules would be ...

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

With those findings in mind, the ABPI recommended in the report that pharmas “explore the appropriate use of social media ...

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...

Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the ...

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...